Imetelstat shows promise for improving overall survival (OS) and symptoms in patients with high-risk myelofibrosis (MF) that has relapsed or is refractory to JAK inhibitors.
FDA Broad Agency Announcement: Frequently Asked Questions for Oncology Researchers
Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.
Findings from the Myelodysplastic Syndromes Natural History Study support the clinical value of targeted interventions for patients at high risk of progression.
Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.
The FDA has granted fast track designation to IMM-1-104 for the treatment of advanced melanoma.
Luspatercept treatment facilitated hemoglobin levels of 10 g/dL or higher and reduced transfusion dependency in patients with lower-risk myelodysplastic syndromes.
PURPOSE The adjuvant treatment for stage III colon cancer (CC) is chemotherapy combining fluoropyrimidine (FP) and oxaliplatin (OX). FP regimen plus OX (FPOX) may benefit…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
On Dec. 21, 1973, Jerry D. Boyd ran the first printing of a little newsletter that would become The Cancer Letter. Today, 50 years later,…
